The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11150 malaria professionals are enjoying the free benefits of MalariaWorld today

children

Safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa: a systematic review and meta-analysis of randomized control trials

January 14, 2022 - 23:41 -- Open Access
Author(s): 
Dawit Getachew Assefa, Eden Dagnachew Zeleke, Wondwosen Molla, Nebiyu Mengistu, Ahmedin Sefa, Andualem Mebratu, Asresu Feleke Bate, Etaferaw Bekele, Gizachew Yesmaw and Eyasu Makonnen
Reference: 
Malaria Journal 2022 21:4, 4 January 2022

The efficacies of artemisinin based combinations have been excellent in Africa, but also comprehensive evidence regarding their safety would be important. The aim of this review was to synthesize available evidence on the safety of dihydroartemisinin-piperaquine (DHA-PQ) compared to artemether-lumefantrine (AL) for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa.

NOT Open Access | Making a good malaria vaccine better

January 5, 2022 - 20:55 -- NOT Open Access
Author(s): 
Duffy PE
Reference: 
Trends Parasitol. 2022 Jan;38(1):9-10

Last month, the World Health Organization (WHO) recommended widespread use of RTS,S/AS01 vaccine to prevent malaria in young African children, noting its 30% reduction in deadly severe malaria.

Not Open Access | Pipecolic acid, a putative mediator of the encephalopathy of cerebral malaria and the experimental model of cerebral malaria

December 28, 2021 - 20:54 -- NOT Open Access
Author(s): 
Keswani T, Obeidallah A, Nieves E, Sidoli S, Fazzari M, Taylor T, Seydel K, Daily JP
Reference: 
J Infect Dis. 2021 Dec 21:jiab615

We explored a metabolic etiology of cerebral malaria (CM) coma.

Trends and predictive factors for treatment failure following artemisinin-based combination therapy among children with uncomplicated malaria in Ghana: 2005-2018

December 23, 2021 - 10:02 -- Open Access
Author(s): 
Abuaku B, Duah-Quashie NO, Quashie N, Gyasi A, Afriyie PO, Owusu-Antwi F, Ghansah A, Malm KL, Bart-Plange C, Koram KA
Reference: 
BMC Infect Dis. 2021 Dec 15;21(1):1255

Since the introduction of artemisinin-based combination therapy (ACT) in Ghana in 2005 there has been a surveillance system by the National Malaria Control Programme (NMCP) and the University of Ghana Noguchi Memorial Institute for Medical Research (UG-NMIMR) to monitor the therapeutic efficacy of ACTs for the treatment of uncomplicated malaria in the country. We report trends and determinants of failure following treatment of Ghanaian children with artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) combinations.

NOT Open Access | Post-malaria neurological syndrome manifesting as new onset psychosis with generalized encephalopathy: an analysis of two cases in children

December 23, 2021 - 09:46 -- NOT Open Access
Author(s): 
Agarwal N
Reference: 
Trop Doct. 2021 Dec 17:494755211055365

Post-malaria neurological syndrome(PMNS) is a rare heterogenous syndrome heralded by the appearance of new neurological or psychiatric manifestations emerging in the post-infectious phase after clearance of malaria parasitaemia. Most cases of PMNS have been described in adults. Only seven cases have been reported in children.

Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children

December 17, 2021 - 21:26 -- Open Access
Author(s): 
Robert M. Mugo, Kennedy Mwai, Jedidah Mwacharo, Faiz M. Shee, Jennifer N. Musyoki, Juliana Wambua, Edward Otieno, Philip Bejon and Francis M. Ndungu
Reference: 
Malaria Journal 2021 20:452, 2 December 2021

RTS,S/AS01, the leading malaria vaccine has been recommended by the WHO for widespread immunization of children at risk. RTS,S/AS01-induced anti-CSP IgG antibodies are associated with the vaccine efficacy. Here, the long-term kinetics of RTS,S/AS01-induced antibodies was investigated.

The Anti-Circumsporozoite Antibody Response Of Children To Seasonal Vaccination With The Rts,S/As01e Malaria Vaccine

December 14, 2021 - 20:32 -- Open Access
Author(s): 
Sagara I, Zongo I, Greenwood B, et al.
Reference: 
Clin Infect Dis. 2021 Dec 11:ciab1017

A trial in young African children showed that combining seasonal vaccination with the RTS,S/AS01E vaccine with seasonal malaria chemoprevention reduced the incidence of uncomplicated and severe malaria substantially compared to either intervention given alone. This paper reports the anti-circumsporozoite antibody response to seasonal RTS,S/AS01E vaccination in children in this trial.

Ethical considerations for introducing RTS,S/AS01 in countries with moderate to high Plasmodium falciparum malaria transmission

December 11, 2021 - 21:51 -- Open Access
Author(s): 
D'Souza J, Nderitu D
Reference: 
Lancet Glob Health. 2021 Dec;9(12):e1642-e1643

On Oct 6, 2021, WHO recommended the widespread use of the RTS,S/ASO1 malaria vaccine (Mosquirix; GlaxoSmithKline, Brentford, UK) among children in areas with moderate to high Plasmodium falciparum malaria transmission.

Marked reduction in antibiotic usage following intensive malaria control in a cohort of Ugandan children

December 7, 2021 - 21:30 -- Open Access
Author(s): 
Krezanoski PJ, Roh ME, Rek J, Nankabirwa JI, Arinaitwe E, Staedke SG, Nayiga S, Hsiang MS, Smith D, Kamya M, Dorsey G
Reference: 
BMC Med. 2021 Nov 30;19(1):294

Intensive malaria control may have additional benefits beyond reducing the incidence of symptomatic malaria. We compared antibiotic treatment of children before and after the implementation of highly effective malaria control interventions in Tororo, a historically high transmission area of Uganda.

Pages

Subscribe to RSS - children